Tarsus Q1 FY26 net loss narrows to $7 million; net product sales rise 85% to $145.4 million

Tarsus Pharmaceuticals, Inc.

Tarsus Pharmaceuticals, Inc.

TARS

0.00
  • Tarsus Pharmaceuticals posted Q1 net sales of USD 145.4 million, up more than 85% year over year.
  • Net loss narrowed to USD 7 million, or USD 0.16 per share.
  • Gross margin held at 94% as cost of sales rose to USD 9.4 million.
  • SG&A expenses climbed to USD 136.4 million, driven by higher commercial and marketing costs including direct-to-consumer advertising.
  • Reaffirmed 2026 net sales guidance of USD 670-700 million for XDEMVY, citing momentum in weekly prescribing and patient demand from its DTC campaign.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tarsus Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605061605PRIMZONEFULLFEED9714692) on May 06, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.